Searchable abstracts of presentations at key conferences in endocrinology

ea0082wa6 | Workshop A: Disorders of the hypothalamus and pituitary | SFEEU2022

Pituitary function tests – Partial empty sella syndrome with panhypopituitarism

Ranasinghe Beatrice , Chhina Navpreet

Case history: 66 year old male referred with a thyrotoxic biochemistry. History was in favour of a subacute thyroiditis with a painful neck and short-term elevation of fT3 and fT4 which have improved to lower limits of normal without any treatment at the time of first clinic visit. He was monitored for thyroiditis and the biochemistry gradually changed and patient started to complain of tiredness. Investigations and treatment: Morning Pituitary profile i...

ea0082wc2 | Workshop C: Disorders of the thyroid gland | SFEEU2022

Thyroid function tests - Thyroid hormone resistance

Ranasinghe Beatrice , Chhina Navpreet

Case history: 61 year old female with a history of inherited dilated cardiomyopathy was referred with abnormal thyroid functions not improving with Levothyroxine. She has been on Levothyroxine 100 mg which she has discontinued 5 months prior to the review but her thyroid function abnormality persisted. She had no family history of thyroid abnormalities.Investigations: Negative TSH receptor antibodies.Treatment and follow up:<table boarder="1" cellpad...

ea0082wd16 | Workshop D: Disorders of the adrenal gland | SFEEU2022

Non-classic congenital adrenal hyperplasia (NCCAH)

Ranasinghe Beatrice , Chhina Navpreet

Case history: 30-year-old female presented with subfertility for a year. She has had menarche at the age of 13 and regular periods for 2 years prior to commencing on hormonal contraception (initially COCP and then implant). Off contraception her menstrual cycles resumed after 6 weeks with a regular cycle length of 24 days. She has also suffered from generalised excessive body hair since young.Investigations: Treatment and follow up: Foll...

ea0069p32 | Poster Presentations | SFENCC2020

An illustrative case highlighting the risk of nephrocalcinosis with 1-alfacalcidol in chronic hypoparathyroidism

Ranasinghe Beatrice , Chinnasamy Eswari

Case history: Twenty-one year-old female with Di-George syndrome, genetically confirmed at the age of 6 years, was on 1-alfacalcidol for chronic hypoparathyroidism. Her initial presentation was with Seizures in childhood. She has been seizure free with treatment of hypocalcaemia. Her serum calcium levels have been fluctuating with intermittent hypercalcaemia over the years.Investigations: Initial results on 1.5 mcg of 1-alfacalcidol OD:<p class="abst...

ea0058p073 | Diabetes | BSPED2018

Psychological spectrum in DM1

Khanna Ankit , Ranasinghe Asankha

AbstractThe psychosocial impact of diabetes in childhood is ubiquitous and involves the entire family, as well as schools and society as a whole. The International Society for Pediatric and Adolescent Diabetes (ISPAD) developed guidelines in 2000 to assist health professionals in the management of young people with diabetes. These guidelines are based on the St. Vincent Declaration, the Declaration of Kos, and the Declaration of the Americas, which defin...

ea0044p33 | Adrenal and Steroids | SFEBES2016

What is the most appropriate cut-off for post-saline aldosterone in saline suppression test after adrenalectomy?

Ranasinghe Ruvini , Taylor David , Whitelaw Benjamin , Aylwin Simon , Vincent Royce

Introduction: Primary aldosteronism (PA) is the most common endocrine cause of hypertension affecting up-to 10% of hypertensives. Saline suppression, a confirmatory test for PA helps avoiding patients undergoing invasive lateralisation procedures due to a false positive aldosterone-to-renin ratio (ARR). The proposed cut-off to exclude PA is post-saline aldosterone suppression to <140 pmol/l. We reviewed our biochemical work-up in order to optimise laboratory assessment.</p...

ea0011p330 | Diabetes, metabolism and cardiovascular | ECE2006

How does glucose insulin potassium improve haemodynamic performance? Evidence for beta-adrenoreceptor and sarcoplasmic reticulum calcium ATPase up-regulation

Ranasinghe AM , Quinn DW , McCabe CJ , Pagano D , Franklyn JA , Bonser RS

Objectives: Glucose insulin potassium (GIK) improves haemodynamic performance following coronary artery bypass graft surgery (CABG). We postulated that this might be secondary to beta-1 adrenergic receptor (ADRB1) up-regulation and changes in myocyte calcium handling.Methods: We performed a randomised double-blind placebo-controlled trial on patients undergoing first time elective/urgent on-pump CABG (LREC approval obtained). A cohort of 48 patients rand...

ea0009p31 | Diabetes and metabolism | BES2005

Elevated endotoxin levels as a mediator of consistent chronic sub-clinical inflammation in CABG patients

Baker A , Silva N , Ranasinghe A , Pagano D , Bonser R , Kumar S , McTernan P

Chronic sub-clinical inflammation is associated with increased risk of type 2 diabetes and cardiovascular disease. Patients undergoing CABG are at high risk of further cardiovascular events and also demonstrate sub-clinical inflammation. We therefore investigated alterations in the relative balance between pro-inflammatory agents, such as hsCRP versus changes in anti-inflammatory factors (adiponectin) and as such the potential molecular pathways mediating these changes. The ai...

ea0086p330 | Metabolism, Obesity and Diabetes | SFEBES2022

Glicentin concentrations following Liraglutide treatment in patients with overweight/obesity

Al-Hasani Wiaam , Ranasinghe Ruvini , Luxton James , Mare Tracey , Dimitriadis Georgios K , Vincent Royce P

Background: Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist that promotes weight loss. The minimum adequate/good response to liraglutide (≥5% weight loss at 3 months) is not achievable in all patients. Currently there are no biomarkers to predict good response. Enhanced postprandial glicentin concentration was recently considered as superior to GLP-1 in predicting weight loss following bariatric surgeries.Objective 1) T...

ea0011oc59 | ThyroidOC57 British Thyroid Association Award | ECE2006

Tri-iodothyronine improves haemodynamic performance and is associated with improved myocardial protection post on-pump coronary artery bypass grafting

Ranasinghe AM , Quinn DW , Graham TR , Keogh BE , Mascaro CJ , Rooney SJ , Wilson IC , Pagano D , Franklyn JA , Bonser RS

Objectives: Tri-iodothyronine (T3) can improve cardiovascular performance following cardiac surgery. Its effects on myocardial protection are unknown.Methods: We performed two consecutive randomised double-blind placebo-controlled trials (identical management protocols) on patients undergoing first time isolated elective or urgent on-pump coronary artery bypass graft surgery (CABG). Between January 2000 and September 2004, 440 patients were re...